Diabetes is no longer just a lifestyle disease, it has become one of the biggest healthcare challenges worldwide.
Every year, millions of new patients are diagnosed with Type 1 or Type 2 diabetes, increasing the demand for insulin, innovative medicines, glucose monitoring devices, insulin pumps, and digital healthcare technologies. As healthcare systems work to reduce diabetes-related complications, leading pharmaceutical and medical device companies are investing billions of dollars to develop more effective and convenient treatment options.
According to the International Diabetes Federation (IDF), nearly 589 million adults aged 20–79 years were living with diabetes in 2025. Without stronger prevention and treatment efforts, that number is expected to reach 853 million by 2050.
Government health agencies also highlight the growing burden. The U.S. Centers for Disease Control and Prevention (CDC) reports that 38.4 million Americans have diabetes, while nearly 97.6 million adults have prediabetes. In India, the Indian Council of Medical Research (ICMR) estimates that around 101 million adults are living with diabetes, making the country one of the largest diabetes markets in the world.
As the patient population grows, the companies leading diabetes innovation are shaping the future of healthcare through advanced medicines, connected devices, and personalized treatment solutions.
Global Diabetes at a Glance
| Metric | Latest Data |
|---|---|
| Adults living with diabetes worldwide | 589 million |
| Expected diabetic population by 2050 | 853 million |
| Adults with diabetes in the United States | 38.4 million |
| Adults with prediabetes in the United States | 97.6 million |
| Adults living with diabetes in India | ~101 million |
| Global diabetes-related healthcare spending | Over US$1 trillion annually |
| Countries with highest diabetes burden | China, India, United States |
Top Diabetes Companies at a Glance
| Rank | Company | Key Diabetes Products | Latest Business Highlights |
|---|---|---|---|
| 1 | Novo Nordisk | Ozempic, Rybelsus, Tresiba, NovoRapid | World’s largest insulin manufacturer with 100+ years of diabetes expertise and GLP-1 medicines used by millions of patients globally. |
| 2 | Eli Lilly | Mounjaro, Trulicity, Humalog, Humulin, Lyumjev | Mounjaro has become one of the fastest-growing diabetes medicines worldwide. The company is investing billions of dollars to expand manufacturing capacity. |
| 3 | Abbott | FreeStyle Libre CGM | More than 7 million people worldwide use FreeStyle Libre sensors across 60+ countries. |
| 4 | Dexcom | Dexcom G7 CGM | A global leader in continuous glucose monitoring with products available in 50+ countries. |
| 5 | Medtronic | MiniMed Insulin Pumps, Guardian CGM | One of the world’s leading insulin pump manufacturers, serving millions of patients globally. |
| 6 | Sanofi | Lantus, Toujeo, Soliqua | Lantus remains among the best-selling long-acting insulin brands worldwide. |
| 7 | Roche | Accu-Chek Monitoring Systems | Accu-Chek blood glucose monitoring devices are used in 100+ countries. |
| 8 | Tandem Diabetes Care | t:slim X2 Insulin Pump | Rapidly growing insulin pump company with hundreds of thousands of active users worldwide. |
Novo Nordisk Continues to Set the Industry Standard
When people think of diabetes treatment, Novo Nordisk is often the first company that comes to mind.
Founded more than a century ago, the Danish pharmaceutical company has built one of the world’s largest diabetes portfolios. Its insulin brands, including NovoRapid, Tresiba, Levemir, Fiasp, Ryzodeg, and Novolin, are prescribed across hospitals and clinics worldwide.
The company’s biggest breakthrough has been Ozempic, which has become one of the world’s highest-selling diabetes medicines. Along with Rybelsus, the first oral GLP-1 therapy, Novo Nordisk has changed how Type 2 diabetes is treated.
The company continues investing billions of dollars in manufacturing expansion and research to meet rapidly increasing global demand.
Looking for data that supports your next business decision? Get a FREE sample customized to your strategic priorities: https://www.towardshealthcare.com/download-sample/6124
Eli Lilly Is Transforming Diabetes Treatment
Eli Lilly has emerged as Novo Nordisk’s biggest competitor in diabetes innovation.
Its blockbuster medicine Mounjaro (tirzepatide) has shown impressive improvements in blood sugar control while also helping many patients achieve meaningful weight loss.
Lilly’s diabetes portfolio also includes trusted insulin products such as Humalog, Humulin, Lyumjev, Basaglar, and Trulicity, making it one of the largest diabetes companies worldwide.
To support growing demand, the company has committed multi-billion-dollar investments to expand manufacturing facilities in the United States.
Abbott Revolutionized Blood Sugar Monitoring
For many years, diabetes patients depended on painful finger-prick tests several times each day.
Abbott changed that experience with its FreeStyle Libre continuous glucose monitoring (CGM) system.
Today, more than 7 million people worldwide use Libre sensors, allowing patients to monitor glucose levels continuously through a wearable device instead of repeated blood tests.
The technology has improved convenience while helping physicians make faster and better treatment decisions.
Dexcom Continues to Lead Premium CGM Technology
Dexcom has become one of the fastest-growing diabetes technology companies.
Its Dexcom G7 system provides real-time glucose readings every few minutes and connects seamlessly with smartphones, smartwatches, and insulin pumps.
The company continues expanding globally through partnerships with healthcare providers and digital health platforms, strengthening its position in connected diabetes care.
Medtronic Is Advancing Automated Insulin Delivery
Treating diabetes involves much more than medicines alone.
Medtronic has become a global leader in insulin pump technology through its MiniMed systems, which automatically adjust insulin delivery using continuous glucose monitoring data.
These smart systems help patients maintain healthier glucose levels while reducing episodes of dangerously low blood sugar.
Sanofi Remains a Trusted Insulin Leader
Sanofi continues to play an important role in global diabetes treatment.
Its long-acting insulin Lantus remains one of the most widely prescribed insulin products in the world.
The company has also expanded its portfolio with Toujeo and combination therapies that provide longer-lasting blood sugar control with fewer daily injections for many patients.
Roche Focuses on Better Diabetes Monitoring
Swiss healthcare company Roche has built a strong reputation through its Accu-Chek blood glucose monitoring systems.
Its devices are trusted by healthcare professionals and patients across more than 100 countries, supporting both home-based monitoring and hospital care.
Roche is increasingly integrating digital technologies that help physicians remotely monitor patient data and personalize treatment plans.
Tandem Diabetes Care Is Growing Rapidly
While pharmaceutical companies dominate diabetes medicines, Tandem Diabetes Care is making significant progress in insulin delivery technology.
Its t:slim X2 insulin pump integrates with continuous glucose monitoring systems to automate insulin dosing and simplify diabetes management.
As demand for smart diabetes devices increases, Tandem continues expanding its presence across international markets.
The Future of Diabetes Care Is Becoming Smarter
Diabetes management is evolving rapidly beyond traditional insulin therapy.
Artificial intelligence, wearable sensors, smartphone applications, cloud-connected monitoring systems, and automated insulin delivery technologies are helping patients manage their condition with greater accuracy and less daily effort.
Leading companies are also investing in digital health platforms that enable physicians to monitor patients remotely and make treatment decisions using real-time health data.
With 589 million people already living with diabetes worldwide and healthcare spending exceeding US$1 trillion every year, diabetes will remain one of the healthcare industry’s largest opportunities and greatest challenges.
Companies including Novo Nordisk, Eli Lilly, Abbott, Dexcom, Medtronic, Sanofi, Roche, and Tandem Diabetes Care are driving innovation through next-generation medicines, connected medical devices, and advanced digital technologies.
As governments, healthcare providers, and industry leaders continue investing in research and patient care, the future of diabetes management is expected to become more personalized, technology-driven, and accessible; improving the lives of millions of people around the world.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium